US · DVA · MEDICAL - CARE FACILITIES
DaVita Inc. (DVA) intrinsic value and stock valuation
$161.03as of 2026-11-21 · Mkt cap 12.11B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
DaVita Inc. DCF and intrinsic value
InvestorsCraft values DVA with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from DVA’s statements →
DaVita Inc. Graham Number
Graham Number: $51.24d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Revolution Medicines, Inc. (RVMD) $161.20
- Align Technology, Inc. (ALGN) $155.17
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
- The Ensign Group, Inc. (ENSG) $176.32
- Universal Health Services, Inc. (UHS) $179.43
- Henry Schein, Inc. (HSIC) $83.52
- Molina Healthcare, Inc. (MOH) $198.39
- Bio-Rad Laboratories, Inc. (BIO) $358.90
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13.6B | $12.8B | $12.1B | $11.6B | $11.6B |
| Operating income | $2.01B | $2.09B | $1.6B | $1.34B | $1.8B |
| Net income | $746.8M | $936.3M | $691.5M | $560.4M | $978.5M |
| EPSd | $8.48M | $10.7M | $7.42M | $5.85M | $8.9M |
| Operating cash flow | $1.89B | $2.02B | $2.06B | $1.56B | $1.93B |
| Capital expenditure | -$-575.86M | -$-555.44M | -$-567.99M | -$-603.43M | -$-641.47M |
| Free cash flow | $1.31B | $1.47B | $1.49B | $961.1M | $1.29B |
| Total assets | $17.5B | $17.3B | $16.9B | $16.9B | $17.1B |
| Total debt | $15B | $12.1B | $11.1B | $11.8B | $12B |
| Net debt | $14.3B | $11.3B | $10.7B | $11.6B | $11.5B |
| Total equity | $1.16B | $2.09B | $2.74B | $2.22B | $2.37B |
| Cash and short-term investments | $782.1M | $846M | $391.7M | $321.8M | $484.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13.6B | $12.8B | $12.1B | $11.6B | $11.6B |
| Cost of revenue | $9.96B | $8.6B | $8.32B | $8.21B | $7.97B |
| Gross profit | $3.68B | $4.22B | $3.82B | $3.4B | $3.65B |
| Research and development expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Selling, general and administrative expenses | $1.67B | $1.54B | $1.47B | $1.36B | $1.2B |
| Other expenses | $0.00 | $588.2M | $743.7M | $706.1M | $653.7M |
| Operating expenses | $1.67B | $2.13B | $2.22B | $2.06B | $1.85B |
| Cost and expenses | $11.6B | $10.7B | $10.5B | $10.3B | $9.82B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $549.7M | $470.5M | $398.6M | $357M | $285.3M |
| Depreciation and amortization | $715.4M | $723.9M | $745.4M | $732.6M | $680.6M |
| Ebitda | $2.64B | $2.72B | $2.32B | $2.06B | $2.48B |
| Operating income | $2.01B | $2.09B | $1.6B | $1.34B | $1.8B |
| Total other income/expenses, net | -$-663.79M | -$-560.09M | -$-425.69M | -$-372.78M | -$-278.88M |
| Income before tax | $1.35B | $1.53B | $1.18B | $966.3M | $1.52B |
| Income tax expense | $293.1M | $279.7M | $220.1M | $198.1M | $306.7M |
| Net income | $746.8M | $936.3M | $691.5M | $560.4M | $978.5M |
| Weighted average shares outstanding | $86.1M | $85M | $90.8M | $93M | $105.2M |
| Weighted average diluted shares outstanding | $88.1M | $87.3M | $93.2M | $95.8M | $110M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $782.1M | $846M | $391.7M | $321.8M | $484.2M |
| Net receivables | $2.96B | $2.56B | $2.42B | $2.55B | $2.41B |
| Inventory | $160.6M | $134.6M | $143.1M | $109.1M | $107.4M |
| Total current assets | $4.06B | $3.75B | $3.14B | $3.16B | $3.17B |
| Property, plant and equipment, net | $5.21B | $5.33B | $5.57B | $5.92B | $6.3B |
| Goodwill and intangible assets | $7.77B | $7.57B | $7.32B | $7.26B | $7.22B |
| Long-term investments | $198.2M | $370.3M | $593.7M | $275.4M | $288.4M |
| Total non-current assets | $13.4B | $13.5B | $13.8B | $13.8B | $14B |
| Total assets | $17.5B | $17.3B | $16.9B | $16.9B | $17.1B |
| Accounts payable | $696.2M | $547.2M | $514.5M | $479.8M | $402.1M |
| Short-term debt | $534.7M | $681.3M | $517.7M | $626.8M | $573.4M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $3.14B | $2.97B | $2.64B | $2.62B | $2.4B |
| Long-term debt | $14.5B | $11.4B | $10.6B | $11.2B | $11.4B |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $13.2B | $12.2B | $11.5B | $12.1B | $12.4B |
| Capital lease obligations | $2.6B | $2.62B | $2.72B | $2.9B | $3.07B |
| Total liabilities | $16.3B | $15.2B | $14.2B | $14.7B | $14.8B |
| Common stock | $70K | $90K | $90K | $90K | $100K |
| Retained earnings | -$-328.43M | $1.53B | $598.3M | $174.5M | $354.3M |
| Accumulated other comprehensive income (loss) | -$-122.78M | -$-310.8M | -$-52.08M | -$-69.19M | -$-139.25M |
| Total equity | $1.16B | $2.09B | $2.74B | $2.22B | $2.37B |
| Total investments | $222.5M | $421.4M | $605.4M | $353.1M | $310.7M |
| Total debt | $15B | $12.1B | $11.1B | $11.8B | $12B |
| Net debt | $14.3B | $11.3B | $10.7B | $11.6B | $11.5B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $1.08B | $1.25B | $691.5M | $781.6M | $1.21B |
| Depreciation and amortization | $715.4M | $723.9M | $745.4M | $732.6M | $680.6M |
| Stock-based compensation | $140M | $102.8M | $112.4M | $95.4M | $102.2M |
| Change in working capital | -$-263.24M | -$-29.82M | $194.5M | $100K | -$-140.64M |
| Accounts receivable | -$-210.63M | -$-29.77M | $172.4M | -$-148.39M | -$-138.14M |
| Inventory | -$-19.95M | $17.9M | -$-32.13M | -$-760K | $5.72M |
| Accounts payable | $128.3M | $1.7M | $26.9M | $87.5M | -$-30.32M |
| Net cash provided by operating activities | $1.89B | $2.02B | $2.06B | $1.56B | $1.93B |
| Investments in property, plant and equipment | -$-575.86M | -$-555.44M | -$-567.99M | -$-603.43M | -$-641.47M |
| Acquisitions, net | -$-144.5M | -$-251.27M | -$-26.39M | -$-89.19M | -$-200.97M |
| Net cash used for investing activities | -$-654.95M | -$-771.43M | -$-771.8M | -$-630.35M | -$-784.73M |
| Common stock issued | $23.3M | $20.5M | $16.9M | $18.6M | $0.00 |
| Common stock repurchased | -$-1.79B | -$-1.39B | -$-272.22M | -$-802.23M | -$-1.6B |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-1.37B | -$-816.94M | -$-1.17B | -$-1.12B | -$-1.08B |
| Net change in cash | -$-122.08M | $415.2M | $125.6M | -$-215.97M | $53.2M |
| Cash at end of period | $757.8M | $879.8M | $464.6M | $339M | $555M |
| Operating cash flow | $1.89B | $2.02B | $2.06B | $1.56B | $1.93B |
| Capital expenditure | -$-575.86M | -$-555.44M | -$-567.99M | -$-603.43M | -$-641.47M |
| Free cash flow | $1.31B | $1.47B | $1.49B | $961.1M | $1.29B |
Line items
Line items
Line items
About DaVita Inc.
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
- CEO
- Javier J. Rodriguez
- Employees
- 78K
- Beta
- 0.88
Included in
Explore
Frequently asked questions
What is the intrinsic value of DaVita Inc. (DVA)?
DaVita Inc. (DVA) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is DVA undervalued?
DVA trades at a price of $161.03 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.